Drug Pricing & Pharmacy Benefit
Expert articles and analysis related to drug pricing & pharmacy benefit.
AI Summary — Last 30 Days
Over the past 30 days, CMS has finalized major adjustments to Medicare Advantage (MA) and Part D payment policies slated for 2027, including a 2.48% average payment increase—substantially above the initial proposal—and a redesign of the Part D risk adjustment model to more distinctly separate MA-PDs and PDPs, impacting plan payment dynamics for high-cost therapies and chronic conditions. These policy changes were announced under the Trump administration, with CMS Administrator Dr. Mehmet Oz overseeing the agency.
Related Articles
Bipartisan bill would cap insulin at $35 per month
Bipartisan bill would cap insulin at $35 per month Becker's Hospital Review
Understanding The Explanations For The 2027 Medicare Drug Price Negotiation Cycle
Understanding The Explanations For The 2027 Medicare Drug Price Negotiation Cycle Health Affairs
IRA Drug Provisions Linked to Significant Drop in Medicare Medication Nonadherence
CVS reaches insulin pricing settlement with FTC
CVS reaches insulin pricing settlement with FTC Health Leaders Media
CVS Caremark, FTC reach settlement in insulin pricing case
CVS Caremark, FTC reach settlement in insulin pricing case Fierce Healthcare
STAT+: FTC strikes proposed deal with CVS over charges its PBM manipulated insulin prices, impeded access
The FTC said the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.
STAT+: White House digs in on ‘most-favored nation’ drug pricing despite Congress’ cool reception
Despite a cool reception from Congress, the White House is looking to intensify its pressure campaign on lawmakers to pass a “most-favored nation" drug pricing bill.
STAT+: Asthma patients suffered as GSK pursued ‘egregious’ price hikes, senator says
After GSK replaced a popular asthma inhaler with an identical product at a higher price, families reported substantial financial and treatment problems, according to a new report.
CVS Health reaches proposed settlement with FTC on insulin pricing
The Federal Trade Commission and CVS Health have reached a proposed settlement over insulin pricing.On March 23, the FTC filed a joint motion to withdraw the matter with respect to Caremark and the pr...
CVS, FTC reach proposed settlement in insulin pricing case
A settlement between CVS' pharmacy benefit manager and antitrust regulators would leave UnitedHealth as the sole holdout in high-profile suit.